Cirrhosis severity tracks with echo-defined cardiac dysfunction in a stable clinic cohort
Cirrhosis does not confine its damage to the liver. In a cross-sectional cohort of 77 clinically stable adults with cirrhosis and no prior cardiovascular disease, worsening liver disease severity lined up with a higher prevalence of cirrhotic cardiomyopathy on echocardiography, along with more diastolic dysfunction and more impaired left ventricular global longitudinal strain. The pattern matters because cirrhotic cardiomyopathy often stays silent until physiologic stress unmasks limited cardiac reserve, leaving patients vulnerable during infection, procedures, bleeding, or decompensation.
The cohort was assessed between September 2023 and September 2024, and the average participant was 61 years old. Men accounted for 50.6% of the sample. Median Child–Pugh and MELD scores were 6 and 11, respectively, placing many participants in relatively early or moderate stages of cirrhosis rather than the sickest end of the spectrum. Even so, cardiac abnormalities were common: diastolic dysfunction appeared in 49.4% of the cohort, impaired LVGLS in 28.6%, and echocardiographically defined cirrhotic cardiomyopathy in 32.5%.
Echo abnormalities rose with worsening liver scores
The clinical separation between liver severity and cardiac performance was not subtle. MELD emerged as an independent correlate of diastolic dysfunction, with an adjusted odds ratio of 1.43 and a 95% confidence interval of 1.15 to 1.78. Child–Pugh score, in contrast, was independently associated with impaired LVGLS and with cirrhotic cardiomyopathy itself. For LVGLS, the adjusted odds ratio was 1.30; for CCM, it was 1.33. Both associations carried statistically significant p values.
One sentence captures the bedside implication: cardiac dysfunction was already present in patients who were clinically stable.
This is the kind of finding that changes how cirrhosis is viewed in routine care. The liver failure phenotype is not isolated from the heart; chronic circulatory changes in cirrhosis can drive hyperdynamic circulation, neurohormonal activation, systemic inflammation, and myocardial remodeling. Over time, those mechanisms can blunt contractile reserve and impair relaxation, even when a standard resting exam looks deceptively reassuring. Strain imaging is particularly useful here because LVGLS can reveal subclinical systolic impairment before a conventional ejection fraction changes enough to trigger concern.
MELD and Child–Pugh may not be interchangeable cardiac risk markers
The study’s most clinically interesting signal was the split between the two liver severity tools. MELD aligned more closely with diastolic dysfunction, while Child–Pugh better tracked with reduced LVGLS and with the composite diagnosis of cirrhotic cardiomyopathy. That separation suggests the scores may be reflecting different dimensions of hepatic illness that map onto different cardiac phenotypes. MELD, built from laboratory variables, may better capture the physiologic burden linked to filling abnormalities. Child–Pugh, which incorporates clinical features of cirrhosis severity, may be more sensitive to the broader systemic state in which myocardial dysfunction becomes evident.
The study also explored candidate thresholds for risk stratification. ROC analysis identified MELD ≥ 10.5 and Child–Pugh ≥ 8.5 as potential cut points for higher CCM risk, with AUC values of 0.708 and 0.691, respectively. These are not practice-changing thresholds yet, and they should not be treated as fixed screening rules. They do, however, offer preliminary reference points for deciding which patients may merit echocardiographic evaluation when resources are limited or when clinical suspicion is rising.
Why subclinical cardiomyopathy matters in cirrhosis care
Cirrhotic cardiomyopathy is easy to miss because it may remain dormant until the cardiovascular system is stressed. A patient can appear hemodynamically compensated in clinic and still have limited ability to augment cardiac output during bleeding, sepsis, anesthesia, or volume shifts. In that setting, what looked like mild liver disease on paper can become a cardiac liability at the bedside. The combination of abnormal diastolic relaxation and impaired longitudinal strain points to a myocardium already struggling with compliance and reserve.
The prevalence figures in this cohort are especially relevant because they were observed in clinically stable adults without known cardiovascular disease. This is not a selected heart failure population. It is a liver clinic population, which is precisely where occult dysfunction can be overlooked. A 32.5% prevalence of CCM in that context argues for more deliberate cardiovascular screening in cirrhosis, particularly once liver severity rises past the range where risk begins to accelerate.
A single echocardiogram will not answer every question, but it can identify the patients least likely to tolerate physiologic stress without difficulty.
Screening implications for routine cirrhosis management
The investigators’ interpretation is restrained and appropriate. The findings support considering cardiovascular screening in patients with cirrhosis, especially when Child–Pugh or MELD scores climb, but the proposed thresholds remain exploratory and require validation in larger prospective cohorts before they can be adopted clinically. Cross-sectional data can show association, not temporal causality. They cannot establish whether progression of liver disease drives myocardial injury over time, whether echo abnormalities predict future decompensation, or whether earlier detection changes outcomes.
Even with those constraints, the practical message is hard to ignore. A MELD score near or above 10.5 may be a signal to look more carefully for diastolic dysfunction. A Child–Pugh score near or above 8.5 may point to a higher likelihood of reduced LVGLS and full cirrhotic cardiomyopathy. In a disease where hepatic and cardiac physiology are tightly linked, those scores may help identify patients who need closer peri-procedural planning, more careful fluid management, or earlier specialist evaluation.
What this cohort can and cannot tell clinicians
The study was modest in size, with 77 participants, and it focused on adults who were clinically stable and already free of known cardiovascular disease. That narrow design strengthens the signal that subclinical dysfunction exists in routine cirrhosis care, but it also limits generalizability. The findings should be read as hypothesis-generating rather than definitive. Larger longitudinal cohorts will need to determine whether these thresholds reproduce across different cirrhosis etiologies, severity distributions, and care settings.
For now, the most defensible conclusion is direct: worsening cirrhosis severity was associated with a higher likelihood of echocardiographically defined cirrhotic cardiomyopathy. The heart is part of the disease burden in cirrhosis, and the echo abnormalities in this cohort suggest that liver scores may help identify patients whose cardiac reserve is already slipping before symptoms make the problem obvious.